日本語フィールド
著者：Yohei Harada, Akemi Sato, Mitsugu Araki, Shigeyuki Matsumoto, Yuta Isaka, Yukari Sagae, Tomonori Abe, Yasuko Aoyagi, Eisaburo Sueoka, Yasushi Okuno, Shinya Kimura, Naoko Sueoka-Aragane題名：Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test 発表情報：Cell Oncol (Dordr) 巻: 45 号: 1 ページ: 121-134キーワード：ERBB2; Extracellular domain; Functional analysis; Molecular dynamics simulation; Variants of unknown significance概要：Purpose: Dealing with variants of unknown significance (VUS) is an important issue in the clinical application of NGS-based cancer gene panel tests. We detected a novel ERBB2 extracellular domain VUS, c.1157A > G p.(E401G), in a cancer gene panel test. Since the mechanisms of activation by ERBB2 extracellular domain (ECD) variants are not fully understood, we aimed to clarify those mechanisms and the biological functions of ERBB2 E401G.
Methods: ERBB2 E401G was selected as VUS for analysis because multiple software tools predicted its pathogenicity. We prepared ERBB2 expression vectors with the E401G variant as well as vectors with S310F and E321G, which are known to be activating mutations. On the basis of wild-type ERBB2 or mutant ERBB2 expression in cell lines without ERBB2 amplification or variants, we evaluated the phosphorylation of human epidermal growth factor receptor 2 and related proteins, and investigated with molecular dynamics (MD) simulation the mechanisms conferred by the variants. The biological effects of ERBB2 E401G were also investigated, both in vitro and in vivo.
Results: We found that ERBB2 E401G enhances C-terminal phosphorylation in a way similar to S310F. MD simulation analysis revealed that these variants maintain the stability of the EGFR-HER2 heterodimer in a ligand-independent manner. Moreover, ERBB2 E401G-transduced cells showed an increased invasive capacity in vitro and an increased tumor growth capacity in vivo.
Conclusion: Our results provide important information on the activating mechanisms of ERBB2 extracellular domain (ECD) variants and illustrate a model workflow integrating wet and dry bench processes for the analysis of VUS detected with cancer gene panel tests.抄録：英語フィールド
Author：Yohei Harada, Akemi Sato, Mitsugu Araki, Shigeyuki Matsumoto, Yuta Isaka, Yukari Sagae, Tomonori Abe, Yasuko Aoyagi, Eisaburo Sueoka, Yasushi Okuno, Shinya Kimura, Naoko Sueoka-AraganeTitle：Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test Announcement information:Cell Oncol (Dordr) Vol: 45 Issue: 1 Page: 121-134Keyword：ERBB2; Extracellular domain; Functional analysis; Molecular dynamics simulation; Variants of unknown significanceAn abstract：Purpose: Dealing with variants of unknown significance (VUS) is an important issue in the clinical application of NGS-based cancer gene panel tests. We detected a novel ERBB2 extracellular domain VUS, c.1157A > G p.(E401G), in a cancer gene panel test. Since the mechanisms of activation by ERBB2 extracellular domain (ECD) variants are not fully understood, we aimed to clarify those mechanisms and the biological functions of ERBB2 E401G.
Methods: ERBB2 E401G was selected as VUS for analysis because multiple software tools predicted its pathogenicity. We prepared ERBB2 expression vectors with the E401G variant as well as vectors with S310F and E321G, which are known to be activating mutations. On the basis of wild-type ERBB2 or mutant ERBB2 expression in cell lines without ERBB2 amplification or variants, we evaluated the phosphorylation of human epidermal growth factor receptor 2 and related proteins, and investigated with molecular dynamics (MD) simulation the mechanisms conferred by the variants. The biological effects of ERBB2 E401G were also investigated, both in vitro and in vivo.
Results: We found that ERBB2 E401G enhances C-terminal phosphorylation in a way similar to S310F. MD simulation analysis revealed that these variants maintain the stability of the EGFR-HER2 heterodimer in a ligand-independent manner. Moreover, ERBB2 E401G-transduced cells showed an increased invasive capacity in vitro and an increased tumor growth capacity in vivo.
Conclusion: Our results provide important information on the activating mechanisms of ERBB2 extracellular domain (ECD) variants and illustrate a model workflow integrating wet and dry bench processes for the analysis of VUS detected with cancer gene panel tests.